The Menarini Group is present in 140 countries worldwide with over 17,500 employees. High-quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability.
These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history. Founded in 1886 in Naples under the name of Farmacia Internazionale, in 1915 Menarini moved to Florence where the Group’s headquarters are located still today.
More recently Menarini has made a commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and/or solid tumours, and through the acquisition of Stemline Therapeutics in June 2020, Menarini strengthened its oncology portfolio with the addition of both commercial and clinical-stage assets.
These assets include ELZONRIS® (tagraxofusp), a targeted therapy directed to the IL-3R (CD123), approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of adult and paediatric patients, with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
In Europe, in January 2021, ELZONRIS® was approved by the EMA as monotherapy for the first-line treatment of adult patients with BPDCN. The acquisition of Stemline established Menarini’s presence in the US biopharmaceutical oncology market, where the company will support further development of Stemline’s assets and will enable global expansion by leveraging its commercial infrastructure in Europe and other ex- US geographies.
Menarini also entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline is preparing for commercialization of ELACESTRANT in the US, Europe and Asia-Pacific.
Most recently Menarini secured their entry into an exclusive licensing agreement, whereby Menarini will commercialize NEXPOVIO, Karyopharm's first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in Europe and other key global territories.
It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.
Menarini Stemline is an equal opportunity employer: We celebrate diversity and are committed to creating an inclusive environment for all employees.
We want to constantly improve our understanding of the disease to enable personalized care from early detection to precision medicine.
We want to make significant impact to oncology treatments, by boldly addressing complex and unexplored unmet needs by game-changing innovation.
We want to become an eponym of scientific and medical excellence recognized as a trusted partner in oncology.
We want to elevate standards of care in oncology, by staying true to our innate caring DNA, to transform every life touched by cancer.